Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

in castrate resistant prostate cancer in 2010, and a third Phase III trial in non-small cell lung cancer in early 2011. OGX-427 is in Phase I clinical development; SN2310 has completed a Phase I clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals ( ISIS), to target and inhibit production of specific proteins which OncoGenex believes are important in tumor progression and treatment resistance. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information is available at www.OncoGenex.com.

OncoGenex's Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, the timing and costs of these activities, the potential benefits of our product candidates, our key 2010 objectives, expectations regarding accrual of clinical trials and timing of release of results of studies, and our anticipated future expenses, revenues, reimbursements, capital and sufficiency of capital. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a num
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015 BioNano Genomics, ... of top research institutes, announced today that a collaboration ... Sinai resulted in the creation of the first comprehensive ... single DNA molecule methods for sequencing and genome mapping. ... provided the comprehensive analysis of the contiguous diploid human ...
(Date:6/29/2015)... , June 29, 2015  Neuralstem, Inc. (NYSE ... technology to develop small molecule and cell therapy treatments ... has been approved for listing on the NASDAQ Capital ... will continue to trade on the NYSE MKT until ... the NASDAQ Capital Market is expected to commence on ...
(Date:6/29/2015)... Calif. , June 29, 2015   Veracyte, ... company pioneering the field of molecular cytology, today announced ... News Group,s prestigious Top Workplaces list for the second ... Workplace winners based solely on an annual survey of ... and honored that the degree to which Veracyte values ...
(Date:6/26/2015)... Mass. , June 26, 2015  SeraCare ... vitro diagnostics manufacturers, today announced that it has ... with the National Cancer Institute (NCI), part of ... materials and positive controls for cancer assays.  The ... mix and accurately quantitate control DNA biosynthetics spiked ...
Breaking Biology Technology:BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3
... Application of the RoboCycler Gradient 96 temperature ... , Stratagenes RoboCycler Gradient 96 temperature cycler ... perform fluorescent-tag cycle,sequencing using the ABI PRISM ... Hot Top Assembly eliminates the need for oil or ...
... Allelic discrimination kits with excellent specificity, sensitivity, and,assay ... Lingyu Chen ,Stratagene , Because of their unique ... differences, making them ideal for mutation detection and,allelic ... developed a,series of Mx4000 molecular beacon allelic discrimination ...
... , Douglas Drake Michelle Cayouette Lisa Filippone ,Bob LeSchofs ,Stratagene , , ... , , Figure 1: The ... Stratagene has developed the new SmartPower , ... electrophoretic application. The SmartPower 4000 power supply has been, ...
Cached Biology Technology:Automated Fluorescent-Tag Cycle Sequencing 2Automated Fluorescent-Tag Cycle Sequencing 3Automated Fluorescent-Tag Cycle Sequencing 4Automated Fluorescent-Tag Cycle Sequencing 5Detect Single Nucleotide Sequence Changes with Mx4000 Molecular Beacon,Allelic Discrimination Kits 2Detect Single Nucleotide Sequence Changes with Mx4000 Molecular Beacon,Allelic Discrimination Kits 3Detect Single Nucleotide Sequence Changes with Mx4000 Molecular Beacon,Allelic Discrimination Kits 4Detect Single Nucleotide Sequence Changes with Mx4000 Molecular Beacon,Allelic Discrimination Kits 5Detect Single Nucleotide Sequence Changes with Mx4000 Molecular Beacon,Allelic Discrimination Kits 6Detect Single Nucleotide Sequence Changes with Mx4000 Molecular Beacon,Allelic Discrimination Kits 7A Versatile Power Supply for All Electrophoresis Applications 2A Versatile Power Supply for All Electrophoresis Applications 3A Versatile Power Supply for All Electrophoresis Applications 4A Versatile Power Supply for All Electrophoresis Applications 5
(Date:6/24/2015)... Switzerland , June 24, 2015 ... partnership with emerging biometric password solution one face ... one face in, entering ... a ground-breaking and affordable multifactor-authentication biometric answer to ... recognition technology, provided in partnership with KeyLemon, one ...
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/17/2015)... and HILDEN, Germany , June 17, 2015 ... Frankfurt Prime Standard: QIA) today launched new Investigator ® ... laboratories in the United States . The ... analyze multiple key genomic markers (short tandem repeats or STRs) ... Sensor to evaluate the quality of DNA in each sample, ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... The Van Andel Research Institute (VARI) and the ... alliance that will enable both to maximize their worldwide ... institutes jointly announced today the initiation of an "alliance ... Rapids, Mich.-based VARI and Phoenix, Ariz.-based TGen will enable ...
... to identify microbes that may cause preterm labor in some ... contractions and an early birth, and look at different groups ... prematurity. The work of seven researchers will be supported ... Prematurity Research Initiative (PRI) grants. The nearly $2.7 million ...
... against respiratory infections, the body typically produces a little fluid ... research suggests that the influenza virus can tip the balance ... supply of oxygen to the rest of the body. ... but this research suggests that it,s not the presence of ...
Cached Biology News:Van Andel Research Institute and TGen undertake alliance to promote science and health 2Van Andel Research Institute and TGen undertake alliance to promote science and health 3March of Dimes provides $2.7 million in new funding for preterm birth research 2March of Dimes provides $2.7 million in new funding for preterm birth research 3Study: Fluid buildup in lungs is part of the damage done by the flu 2Study: Fluid buildup in lungs is part of the damage done by the flu 3
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... service, ExonHit can design custom microarrays to ... gene list. Proprietary algorithms are used ... probes from high quality, spliced cDNAs aligned ... contained in a custom SpliceArray is profiled ...
... Visualizer DX's sensitivity of DNA detection has been ... in an agarose gel can be detected > ... can be purified by organic solvent extraction or ... kits worked well.) DNA excised from agarose ...
... SPE Workstation is a modular, highly scalable, ... Utilizing 1ml or 3ml industry standard SPE ... 100 samples in less than two hours ... 10 cartridges, and up to 10 modules ...
Biology Products: